Skip to content
Login
Access EMAS Membership
Search
Home
About EMAS
Membership
Journals
Junior Section
JuMP programme
Travel grant
Research grant
Svg Vector Icons : http://www.onlinewebfonts.com/icon
What we do
Upcoming webinars
Webinars on-demand
Podcasts
Menopause in the Workplace
Menopause training for HCPs
EMAS School
Research updates
News
Guidelines and education
Congresses / Courses
Viatris – EMAS 2023
Contact
Login
Access EMAS Membership
Linkedin
Instagram
Youtube
Threads
Risk assessment for MHT – When, to whom, which, and how long? (PT)
4 years ago
Andres Daste
,
Antonio Cano
You may also like
Menopause and Work Day Webinar 2021 | What healthcare professionals need to know
10 months ago
Antonio Cano
,
Emma Persand
,
Margaret Rees
Impact of estrogen deficiency on quality of life in Asia and the role of continuous combined MHT in treatment (PT)
2 years ago
Dayong Lee
,
Petra Stute
,
Qi Yu
How to handle the daily practice challenges when prescribing oral MHT (PT)
2 years ago
Eleni Armeni
,
Khulood Al Awadi
,
Naoual Merrouche
Benefits of oral combined MHT for estrogen deficiency symptoms treatment (PT)
2 years ago
Angelica Hirschberg
,
José Vázquez
,
Patricio Barriga
Personalized oral combined MHT and long-term effects: How to choose according to the patient’s needs (PT)
2 years ago
Larysa Mishchenko
,
Suvarna Khadilkar
,
Tim Hillard
Practical Aspects of MHT: Regimen, dosage, duration of treatment, and adverse events handling (PT)
3 years ago
Dimitrios Goulis
,
Nozer Sheriar
,
Tobie de Villiers
Menopause beyond hot flushes: How to address common symptoms in the Asian population? (PT)
3 years ago
Alfred Mueck
,
Bohyon Yun
,
Qi Yu
The long-term effects of oral combined estrogen + progestogen: Which patient profile benefits the most? (PT)
3 years ago
Eleni Armeni
,
José Vázquez
,
Paulina Villaseca
Progestágenos y cáncer
3 years ago
Antonio Cano
EMAS Roundtable: Hot issues on menopause (PT)
3 years ago
Antonina Smetnik
,
Dimitrios Goulis
,
EMAS Roundtable
,
Rebecca Thurston
See all Webinars
X